In particular, targeting upstream activators such as protein arginine N-methyltransferase-4 (PRMT4), thioredoxin reductase 1 (TXNRD1), and Keap1 mutations, as well as exploring combination strategies with ferroptosis inducers and immune checkpoint inhibitors, may unlock new avenues in cancer treatment [32,33,34]. This evidence concerns the gene TXNRD1 and cancer.